Want to join the conversation?
Biopharmaceutical company $BXLT said it has launched ADYNOVATE, a new treatment to control bleeding episodes in adult patients with Hemophilia A with a simple twice-weekly dosing schedule, in the U.S. Market. ADYNOVATE was developed through a collaboration with $NKTR and was approved by U.S. FDA in Nov. 2015.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?